| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Sushmita Sinha | Q59677276 |
| Halina Offner | Q89146584 | ||
| P2093 | author name string | Arthur A Vandenbark | |
| Gregory G Burrows | |||
| Chunhe Wang | |||
| P2860 | cites work | Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen | Q27748865 |
| A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis | Q28251844 | ||
| Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis | Q28584050 | ||
| IL-17 family cytokines and the expanding diversity of effector T cell lineages | Q29619361 | ||
| Signal transduction by lymphocyte antigen receptors | Q29619894 | ||
| Cytokines and the central nervous system | Q34221106 | ||
| Multiple sclerosis: more than inflammation and demyelination | Q34327785 | ||
| Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. | Q34413750 | ||
| Axonal injury in multiple sclerosis | Q35105813 | ||
| Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. | Q36189566 | ||
| Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. | Q36329275 | ||
| Models of T cell anergy: is there a common molecular mechanism? | Q36366967 | ||
| Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands | Q36367500 | ||
| Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis | Q36368128 | ||
| T(H)-17 cells in the circle of immunity and autoimmunity | Q36765453 | ||
| Pathogenesis of axonal and neuronal damage in multiple sclerosis | Q36840382 | ||
| Natalizumab for multiple sclerosis | Q36854538 | ||
| MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8 | Q38329233 | ||
| Multiple sclerosis: an immunologic reassessment | Q39897571 | ||
| T-Cell-Mediated Immunopathology in Viral Infections | Q39943334 | ||
| Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury | Q40390990 | ||
| Regulation and function of p21ras in T lymphocytes. | Q40508456 | ||
| Regulation of encephalitogenic T cells with recombinant TCR ligands | Q40875297 | ||
| Altered T cell receptor ligands trigger a subset of early T cell signals | Q41180292 | ||
| Myelin basic protein specific T cell lines and clones derived from the CNS of rats with EAE only recognize encephalitogenic epitopes | Q41663454 | ||
| Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides | Q43794379 | ||
| Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation | Q44539452 | ||
| Opposing roles for TGF-beta1 and TGF-beta3 isoforms in experimental autoimmune encephalomyelitis | Q44704488 | ||
| Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. | Q44870661 | ||
| Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis | Q45351794 | ||
| Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. | Q46007698 | ||
| Ligand recognition by alpha beta T cell receptors | Q46222293 | ||
| Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis | Q46253564 | ||
| Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice | Q47817045 | ||
| Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch | Q47914644 | ||
| Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b | Q48718477 | ||
| Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 | ||
| A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. | Q50657622 | ||
| Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. | Q52443678 | ||
| Definition of encephalitogenic and immunodominant epitopes of guinea pig myelin basic protein (Gp-BP) in Lewis rats tolerized neonatally with Gp-BP or Gp-BP peptides. | Q54199477 | ||
| Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. | Q55480343 | ||
| α4Integrins as Therapeutic Targets in Autoimmune Disease | Q58199770 | ||
| Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness | Q70179724 | ||
| The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis | Q72249443 | ||
| Design, engineering and production of functional single-chain T cell receptor ligands | Q73041460 | ||
| Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2 | Q73798778 | ||
| Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results | Q74009726 | ||
| Demyelinating diseases--new pathological insights, new therapeutic targets | Q74100782 | ||
| Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells | Q74601834 | ||
| Cutting edge: trimolecular interaction of TCR with MHC class II and bacterial superantigen shows a similar affinity to MHC:peptide ligands | Q77929073 | ||
| Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice | Q79674405 | ||
| P433 | issue | 4-5 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 327-339 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Reviews in the Neurosciences | Q15750651 |
| P1476 | title | Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis | |
| P478 | volume | 19 |
| Q61445020 | A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury |
| Q34077153 | Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. |
| Q34350992 | Characterization of human platelet binding of recombinant T cell receptor ligand. |
| Q37149410 | Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis |
| Q37351198 | Induction of tolerance against the arthritogenic antigen with type-II collagen peptide-linked soluble MHC class II molecules |
| Q35722702 | Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity |
| Q35797272 | Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice |
| Q28742932 | RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS |
| Q35893543 | Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study |
| Q33645392 | Sex-dependent treatment of chronic EAE with partial MHC class II constructs |
| Q36231789 | Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in Royal College of Surgeons rats. |
| Q35036755 | Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice |
Search more.